Glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin therapies form a family of medicines that act on hormones involved in glucose regulation, appetite, and energy balance. This class includes selective GLP-1 receptor agonists as well as newer dual and triple agonists that also engage receptors for GIP and, in some cases, glucagon.

At a high level, these agents are used and studied in the context of type 2 diabetes, chronic weight management, and broader metabolic health, with specific labeled indications varying by molecule and jurisdiction.

Although individual molecules differ, many GLP-1 and incretin-based therapies share a set of recurring mechanistic themes:

• Enhancing glucose-dependent insulin secretion from pancreatic beta cells
• Modulating glucagon secretion in a way that supports glycemic control
• Slowing gastric emptying and affecting postprandial glucose
• Acting on appetite-regulating centers in the brain to reduce hunger and energy intake in many individuals

Dual and triple agonists extend these ideas by engaging additional receptors, which may influence energy expenditure, lipid handling, or other metabolic pathways. Exactly how these mechanisms combine in humans is an active area of research.

Depending on region and product, members of this class may be approved for use in adults with type 2 diabetes, for chronic weight management in certain populations, or in other specific indications defined by local regulators. Eligibility criteria, dosing regimens, and labeled uses are molecule- and jurisdiction-specific.

Outside formal labeling, GLP-1 and related incretin therapies are often discussed more broadly in conversations about obesity, metabolic syndrome, and cardiometabolic risk. Any consideration of use should stay anchored in local regulations, official product information, and clinician judgment.

Across GLP-1 and related incretin therapies, commonly reported side effects in studies have included gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), decreased appetite, and abdominal discomfort. These effects are often dose-related and may be mitigated by gradual dose escalation.

More serious but less frequent risks under active study include gallbladder-related issues, pancreatitis, and class-wide questions about long-term safety in specific populations. Risk–benefit decisions, contraindications, and monitoring strategies are molecule- and patient-specific and belong with prescribing clinicians.

Within this catalog, several peptides fall into or adjacent to the GLP-1 and incretin class, including selective GLP-1 receptor agonists, dual GIP/GLP-1 agonists, triple agonists, and amylin analogs or combinations that build on similar metabolic themes.

Commercial products may appear as once-weekly injectables, oral formulations, or other delivery systems. Catalog listings here are structural references only and do not comment on the appropriateness of any specific formulation, source, or compounding approach.

Research across this class includes large randomized trials in type 2 diabetes and obesity, as well as studies focused on cardiovascular outcomes, liver and kidney endpoints, and quality-of-life measures.

Because the evidence base continues to evolve, this section should be read as a snapshot of common themes rather than a comprehensive or permanently current review. Clinical and personal decisions should be informed by up-to-date primary literature and trusted guidelines.

If you want a rough sense of how height and weight map to BMI categories often used in research, you can experiment with the educationalBMI calculator.

Over time, this section may host high-level questions such as how GLP-1 receptor agonists compare conceptually with dual or triple agonists, what kinds of outcomes are typically measured in trials, and how clinicians think about class-wide safety themes. Answers will remain educational and non-prescriptive.